2022 World Conference on Lung Cancer (ePosters)-EP07.03-002. Combined Classifications for Thymoma and Thymic Carcinoma From a 10 years CHUM University Hospital Real-world Experience

EP07.03-002. Combined Classifications for Thymoma and Thymic Carcinoma From a 10 years CHUM University Hospital Real-world Experience

Back to course

Pdf Summary

This study aimed to evaluate the overall survival outcomes of patients with thymomas and thymic carcinomas, as well as other secondary objectives such as evaluating survival according to Masaoka and WHO stages, describing treatment modalities, and exploring the combination of staging classifications for better prognostic tools.<br /><br />The study was conducted using data from the SARDO oncologic database, medical electronic records, and a pathology registry. Inclusion criteria included being older than 18 years, having a confirmed diagnosis of thymoma or thymic carcinoma supported by a biopsy, and having at least one year of follow-up.<br /><br />The results of the study revealed that the combination of the WHO and Masaoka staging classifications improved the predictive value of negative margins resectability. Neoadjuvant therapy was found to be a possible option for stages II and IV in order to reduce positive margins, especially for WHO histology B and C.<br /><br />The study also provided demographic and tumoral characteristics of the patient population, including sex, age at diagnosis, smoking status, and paraneoplastic syndrome incidence. The histological characteristics of the tumors were also described, including the subtype of thymoma and thymic carcinoma.<br /><br />The treatments, resection rates, and surgical margins were analyzed, showing that neoadjuvant treatment was more common in stage II and IV tumors. The overall survival rates were presented according to Masaoka and WHO staging, with higher survival rates observed for early-stage tumors.<br /><br />In conclusion, the study suggests that combining different staging classifications can improve the prognostic value for thymomas and thymic carcinomas. The findings also indicate the potential benefit of neoadjuvant therapy in certain stages and histological subtypes. However, further validation in larger cohorts is needed.

Asset Subtitle

Camille Gauvin

Meta Tag

Speaker Camille Gauvin

Topic Mesothelioma, Thymoma, and Other Thoracic Malignancies - Thymoma

Keywords

overall survival outcomes

thymomas

thymic carcinomas

Masaoka stage

WHO stage

neoadjuvant therapy

histological characteristics

treatment analysis

overall survival rates

prognostic value